AtriCure, Inc.

As of October 31, 2025, AtriCure, Inc. shows a mildly bullish trend supported by daily moving averages and monthly KST signals, but mixed indicators from weekly MACD and Bollinger Bands suggest caution, especially given its underperformance compared to the S&P 500.

As of October 31, 2025, AtriCure, Inc. shows a mildly bullish technical trend with positive momentum indicators, but mixed signals from the OBV and underperformance compared to the S&P 500 suggest caution.

As of October 31, 2025, AtriCure, Inc. shows a mildly bullish technical trend with positive momentum from MACD and moving averages, but mixed signals from OBV and performance lagging behind the S&P 500 suggest caution.

As of September 12, 2025, AtriCure, Inc. has a neutral technical trend with mixed indicators, outperforming the S&P 500 year-to-date and over the past year, but showing significantly negative long-term returns compared to the index.

As of November 1, 2022, AtriCure, Inc. has shifted to a risky valuation grade, appearing overvalued with concerning metrics such as a Price to Book Value of 3.80, a negative ROCE of -5.50%, and a P/E ratio of -92.43, despite a strong year-to-date return of 19.96%, which still lags behind the S&P 500 over the long term.

As of November 1, 2022, AtriCure, Inc. is considered overvalued with significant operational challenges reflected in negative earnings and poor return metrics, despite a 39.06% return over the past year, indicating a shift from fair to risky valuation.

As of June 5, 2025, the market trend is mildly bearish, indicated by bearish signals from the weekly MACD, KST, and daily moving averages, despite some bullish signs in monthly indicators.

As of March 2022, the management team of AtriCure, Inc. includes Scott Drake (Independent Chairman), Michael Carrel (CEO), and several independent directors: Mark Collar, Daniel Florin, Regina Groves, B. Kristine Johnson, and Mark Lanning. They oversee the company's strategic direction and operations.

AtriCure, Inc. develops and sells devices for surgical ablation of cardiac tissue and left atrial appendage exclusion, focusing on atrial fibrillation solutions. As of March 2025, it reported net sales of $124 million and a net loss of $7 million, with a market cap of approximately $1.61 billion.

As of Jun 18, AtriCure, Inc. has a market capitalization of $1.61 billion, with net sales of $480.08 million and a net profit of -$38.18 million over the latest four quarters. Shareholder's funds are $460.97 million, and total assets amount to $609.33 million.